can 1 -100 cdc 15-2 ura3 leu2-3.1 12 h1s3-1 1 trp 1 -1 and contained various comb~nat~ons of cdcl3-1 radS::HISS, and rad24::TRPl. The bar1 mutatlon was present to ensure that G, arrest was eff~cient. The cdc15-2 mutation was present to ensure that checkpo~nt control mutants repl~cated the~r DNA only once. At 36"C, c d c l 5 mutants ntiate anaphase but are unable to colnplete nuclear div~sion We modfled the method of Gawk et a/, and cut purifed yeast DNA w~t h Eco RI before applying the DNA to a slot blot apparatus (8) D~fferent flters were probed with GT, AC (from pHR85-31), and URA3 ss RNA probes. Eco RI was necessary because n some experiments ss DNA was present In a non-strandand non-locus-specifc fashion Ths ss DNA did not depend on the presence or absence of CDC13 Our Interpretation s that it represented replcaton forks moving through the chrolnosome Th~s lnconsstent cdcl3-~ndependent s~gnal dsappeared after cuttng of the DNA w~t h Eco RI presumably because the chance that a replication fork was attached to the locus we were prob~ng was reduced. After cuttng w t h Eco RI, lnost (>959=) of the DNA d~d not b~n d to the filter, even after ~t was denatured We assume t h s was because slnaler fragments of DNA b n d the flter less effc~enty. The ss DNA Index increased for two reasons F~rst ss DNA 1s created in v~vo. Second, as ss DNA 1s created, Eco R sites are destroyed, so that the sze of the ss DNA increased and ~t bound the nylon lnelnbrane more eff~cently Therefore we cannot lnake quantitatve deduct~ons aboi~t the amount of ss DNA produced 19. Snge-letter abbrev~at~ons for the amino a c d resldues are as follows: A Ala C, Cys, D Asp; E Glu; F Phe; G, Gly, H His I le; K Lys, L, Leu; M Met, N Asn. P, Pro; Q Gln. R, Arg; S Ser. T Thr, V. Val The phosphorylation of the human estrogen receptor (ER) serine residue at position 11 8 is required for full activity of the ER activation function 1 (AF-1). This Serqq8 is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro and in cells treated with epidermal growth factor (EGF) and insulin-like growth factor (IGF) in vivo. Overexpression of MAPK kinase (MAPKK) or of the guanine nucleotide binding protein Ras, both of which activate MAPK, enhanced estrogen-induced and antiestrogen (tamoxifen)-induced transcriptional activity of wild-type ER, but not that of a mutant ER with an alanine in place of Serqi8. Thus, the activity of the amino-terminal AF-I of the ER is modulated by the phosphorylation of Serqq8 through the Ras-MAPK cascade of the growth factor signaling pathways.
T h e ER belongs to a superfamily of ligandmones, vitamin D3, and retinoic acid, as inducible transcription factors that includes well as peroxisome proliferator-activated receptors for steroid hormones, thyroid horreceptors and orphan receptors (1). The ER has two trallscriptional activation f~~n c - (human, mouse, rat, chick, Xenopus, and trout) and correspond to the consensus phosphorylation site [PX,(S or T)P] (where X is a neutral .or basic amino acid and n = 1 or 2) for MAPK (1 1). The finding that the ligand-induced transcriptional activity of ER can be further enhanced by growth factors such as EGF and IGF (1 2) suggests a possible cross talk between the E2 signaling pathway and growth factor signaling pathways. MAPK is activated by growth factors such as EGF, insulin, and IGF, through membrane-associated receptor tyrosine kinases, which in turn activate Ras followed by activation of the protein kinase Raf. Activated Raf then mediates signal transduction to MAPK through the MAPKK or extracellular signal-regulated protein kinase (ERK) kinases (MEKs) (13) . Taken together, these observations suggested that phosphorylation of the ER Ser118 residue through the growth factor-Ras-Raf-MAPK cascade may modulate the activity of AF-1. T o determine whether Ser118 was phosphorylated by MAPK in vitro, we expressed the human ER (hER) truncated mutant HE15, which contains regions A through C (2) , and its Ser118 mutants HE151457 and HE151458 ( Fig. 1 ) (7) as glutathione-stransferase (GST) fusion proteins in Escherichia coli ( Fig. 2A) . Purified recombinant HE15 ( Fig. 2A ) was phosphorylated by MAPK purified from Xenopus oocytes (14) , under conditions in which myelin basic protein (MBP) was a good substrate for MAPK (Fig. 2B) . Mutation of Ser118 to Ala118 (HE151457) or to Glu118 (HE151 458) abolished phosphorylation (Fig. 2B) 1.2 + 0.1 Fig. 1 . Abrogation of k-Ras-induced activation of AF-1 by mutation of Ser118, but not of Serlo2, Serlo4, and SerlOG (10) . Amino acids 99 to 120 of the hER and the point mutations that were created in theA/B region (7) are shown. COS-1 cells were cotransfected with ERE-G-CAT and each of the HE1 5 mutants (7) in the absence or presence of the expression vector for k-RasVa112, and the relative amounts of chloramphenicol acetyltransferase (CAT) activity were determined as in Fig. 3 . Values for induction by k-RasVa112 (average ? SEM) for six independent experiments are given.
antibody directed against Xenopus MAPK, gave similar results (15) . In contrast, purified recombinant HE15, HE151457, and HE151 458 proteins were not phosphorylated by adenosine 3',5'-monophosphate (CAMP)-dependent protein kinase (PKA), although PKA did phosphorylate histones (Fig. 2B) . We used an electrophoretic mobility-shift assay to show that E. coli-produced or in vitro translated HE15 and HE151457 efficiently bound to an estrogen response element (ERE) and that their binding was not affected by MAPK phosphorylation (15) . The mutation of Ser118 did not affect ERE binding by ER produced in cultured cells (7), and our findings are in agreement with this result.
To examine the ability of growth factors to induce phosphorylation of hER Ser118, we transfected COS-1 cells with HE15 or HE151457 ( Fig. 1 ) and incubated them with and purified HE15 and derivatives (500 ng) (28) were analyzed by electrophoresis on an SDS gel (1 2%. polyacrylamide) and stained with Coomassie blue. Positions of GST fusion proteins and recombinant proteins after cleavage are indicated by open and solid arrowheads,
[32P]orthophosphate in the presence or absence of EGF or IGF. Immunoprecipitation of cell extracts showed that phosphorylation of HE15 was enhanced in cells treated with EGF or IGF (Fig. 2, C and D) , whereas no enhancement was observed when Ser118 was mutated (HE151457). Similarly, expression of a dominant active form of MAPKK (1 6) induced phosphorylation of HE15, but not of HE151457, in transfected COS-1 cells (Fig. 2C) ,
To investigate whether MAPK could be involved in ER-mediated transcriptional activation, we transiently transfected COS-1 cells with the wild-type hER expression vector HEGO (Fig. 3A) and with an expression vector for either c-Ki-Ras (k-Ras) or the dominant active mutant c-Ki-RasVa1l2 (k- . In (C), the expression vector for a dominant active form of MAPKK (400 ng) (15, 16) was cotransfected as indicated. Starvation with phosphate-and serum-free Dulbecco's modified Eagle's medium (DMEM) was done 40 hours after transfection. After 5 hours of starvation, in vivo labeling was done for 4 hours in phosphate-and serum-free DMEM containing 50 pM vanadate, 50 nM okadaic acid, and 1 mCi of [32P]orthophosphate. In (C) and (D), EGF (1 00 ng/ml) was added as indicated; in (D), EGF and IGF (1 00 ng/ml) were added 15 min before harvesting. 32P-labeled extracts of HE15 and HE15/457 were immunoprecipitated with the monoclonal antibody (mAb) B10, followed by SDS-PAGE analysis and immunoblotting, as described (7 (Fig. 3, B and C) . Similar results were obtained in HeLa cells (15) . Because there are two transcriptional activation functions (AF-1 and AF-2) in the ER, we investigated whether k-Ras could activate AF-1 or AF-2 with the hER truncated mutants HE15 and HEG19, respectively (Fig.  3A) . Transactivation by AF-2 (HEG19) was not enhanced by cotransfection of k-Ras or k-RasVaUZ, whereas the activity of AF-1 Enhanced estrogen-induced transcriptional activity of the hER through AF-1 in cells overexpressing k-Ras. ERE-G-CAT was constructed by inserting a synthetic oligonucleotide containing a perfect palindromic ERE into pG-CAT (29) . Transient transfections and CAT assays were done as described (7, 29) . COS-1 cells were cotransfected with either 1 pg of ERE-G-CAT (B) or 2 pg of ERE-TATA-CAT (C) and 0.5 pg of receptor expression vector HEGO, HE15, HEG19, or HE457, in the presence and absence of 10 nM E,, as indicated. Expression vectors (0.5 pg) for kRas (R) and k-RasVa112 (Rq2) (17) were also cotransfected as indicated. Representative CAT assays and graphs corresponding to means and SEM for three independent experiments are shown. 
ERE-TATA-CAT
(HE15) was clearly enhanced, as measured with either of the two reporter genes in COS-1 cells (Fig. 3, B and C) . These observations indicate that enhancement by k-Ras of E2-induced transactivation by hER is essentially mediated through AF-1. An S118A substitution in HEGO (HE457) (Fig. 3A) not only decreased the transcriptional activity of the hER, but also abolished k-Ras-mediated enhancement of transcription from both the ERE-TATA-CAT and ERE-G-CAT reporter genes (Fig.  3, B and C) . In the absence of AF-2 (HE15) (Fig. 3A) , the S118A mutation also abolished k-Ras-mediated transcriptional activation of both reporter genes (Fig. 4A) . In sharp contrast, mutations of Serlo2, Serlo4, or Serlo6 to nonphosphorylatable residues did not affect k-Ras-induced transactivation (Fig. I) , which indicated a specific role for Ser118 in this induction.
We used chimeric proteins in which the A/B region was linked to the GAL4 DNA binding domain (AB-GAL) (Fig. 4B ) to confirm that MAPK-induced activation of hER was the result of enhanced AF-1 activity. In cells transfected with the 17M2-G-CAT reporter gene, which contains two GAL4 17M binding sites located upstream of the globin promoter region (3), expression of k-Ras or of a dominant active form of MAPKK (1 6) enhanced the activation of transcription by AB-GAL (Fig. 4B) , and the S118A mutation (ABl457-GAL) abolished these effects. In contrast, expression of CL100, a MAPK-specific phosphatase (18) , decreased the activation of transcription by AB-GAL (Fig. 4B) . Thus, it appears that MAPK increases the activity of AF-1 by inducing the phosphorylation of Ser118. To determine whether PKA also affects the activity of AF-1, we transfected COS-1 cells with the AB-GAL expression vector and then either cotransfected these cells with a PKA expression vector or Representative CAT assays and graphs corresponding to means and SEM for three independent ex-treated them with forskolin and isobutylmethylxanthine (IBMX) to induce accumulation of CAMP. In both instances, there was no effect on transcription of the 17M2-G-CAT reporter (Fig. 4C ), in agreement with the absence of phosphorylation of purified HE15 protein by PKA in vitro (Fig. 2B) . The antiestrogen 4-hydroxytamoxifen (OHT) has mixed agonistic and antagonistic activities, whereas ICI 164,384 acts as a pure antiestrogen (4, 7, 19) . Although OHT and ICI 164,384 do not appear to inhibit the DNA binding of the receptor, OHT blocks the activity of AF-2 but not of AF-1, whereas ICI 164,384 blocks the activities of both AF-1 and AF-2 (4, 19) . We investigated the effect of k-Ras on transcriptional activation by HEGO in COS-1 cells with the use of the ERE-G-CAT reporter gene in the presence of E2, OHT, or ICI 164,384. The partial agonistic activity of OHT was enhanced in cells transfected with k-Ras, whereas k-Ras had no effect in the presence of ICI 164,384 (Fig. 5 ).
Taken together, our results indicate that transcriptional activation by a member of the nuclear receptor superfamily (ER) can be induced by growth factors (EGF and IGF). This effect is mediated through the membrane-associated receptor tyrosine kinaseRas-Raf-MAPK cascade, which enhances the activity of ER AF-1 by stimulating phosphorylation of the Ser118 residue located in the NH2-terminal A/B region. Although only the Ras-mediated pathway of MAPK activation was examined here, other MAPK activation pathways (13) may also lead to enhanced activity of ER AF-1. Also, MAPK may phosphorylate and regulate other members of the nuclear receptor superfamily.
EGF, TGFa, and IGF-I, which promote the growth of several breast cancer-derived cell lines in culture, are produced by some COS-1 cells were cotransfected with ERE-G-CAT, HEGO, and k-Ras (R) or k-RasVa112 (R12), as indicated, and were grown in the presence or absence of 10 nM E,, 100 nM OHT, or 100 nM ICI 164,384 (ICI). CAT activities were determined as in Fig. 3 . Representative CAT assays and graphs corresponding to means and SEM for three independent experiments are shown. breast tumors in vivo (20) . The c-ErbB2 protein (also called HER2-Neu, a proto-oncogene product related to the EGF receptor) is overexpressed in -20% of human breast cancers, which leads to amplification of the Ras signaling pathway and may cause an aggressive tumor phenotype (2 1). Overexpression of c-ErbB3, another member of the same family, has also been observed in 13 to 29% of breast cancers (22) . Activating Ras mutations are found at a low frequency in primary breast cancers and metastatic effusions (23) , and increased amounts of Ras protein have been found in malignant tissues (24) . Our results suggest that the deregulation of phosphorylation of the Serl l8 residue could be involved in the adverse effect of these growth factors and oncogenes in breast cancer.
Tamoxifen has estrogen-like agonistic activity on some ER-positive breast cancer cells in culture (25) . Because our results show that OHT was almost as efficient as E2 for the enhancement of the transcriptional activity of the ER in the presence of Ras, it is possible that MAPK-activated by growth factors, "activated" Ras, or both-may contribute to an enhanced agonistic activity of OHT, and therefore to the OHT resistance of some breast cancers. ER variants that bear deletions in the ligand-binding domain while maintaining the NH2-terminal A/B region and the DNA-binding domain have been identified in some breast tumors (26) . Our data suggest that such mutants would still be able to mediate the effect of growth factors, Ras, or both through Ser118 phosphorylation. Finally, our results may account for the estrogen-like effect of tamoxifen on bones, where it prevents osteoporosis (27) .
Enhancement of transcription of bone estrogen-responsive genes may depend mainly on the growth factor-activated AF-1 of the ER, and not on AF-2, which is induced by estrogens but is inhibited by tamoxifen.
